Segmed: Breast Cancer Imaging - Digital Breast Tomosynthesis (DBT)

Segmed

Segmed streamlines access to diverse, high-quality real-world data, including medical imaging and clinical records. Segmed’s platform allows for building fit-for-purpose datasets with access to approximately 30 million patients including 150 million de-identified standardized imaging datasets and associated clinical data through a global network of healthcare partners across five continents. This specific dataset contains digital breast tomosynthesis (DBT) exams of 558 patients with breast imaging reporting and data system (BI-RADS) scores of 0, 1, or 2. 271 patients have biopsy proven malignant lesions and 287 patients were benign. Each case contains at least one DBT examination in combination with prior and follow-up breast exams, expert annotations and free-text radiology reports that describe the radiological findings, produced in routine clinical practice. To protect patient privacy, all images and reports have been de-identified.

Breast Cancer Imaging - Digital Breast Tomosynthesis (DBT)
Segmed
Oncology
Breast Cancer
Segmed logo

Datasets

Segmed: Breast Cancer Imaging - Digital Breast Tomosynthesis (DBT)

Data Collection Time Frame

November 2017 - January 2024

Participants

Current: 558

Geographical Coverage

Midwest USA

Usage examples

Digital breast tomosynthesis (DBT) is a powerful imaging modality that allows for improved lesion visibility, characterization, and localization compared to conventional two-dimensional digital mammography. DBT has been increasingly adopted in screening and diagnostic settings globally, particularly for women with dense breast tissue where tissue overlap presents a significant diagnostic challenge. Use cases include, but are not limited to:

  • AI development (training data, enrichment data, or validation data for the development of AI models for lesion detection and/or characterization on DBT images).
  • Biomarker discovery relevant to breast cancer (e.g. radiomics)
  • Clinical development
  • Post-marketing surveillance

Note that Segmed’s data is available through Datavant for overlap assessment.

Data modalities

Clinical data

  • Demographics
  • Radiology reports

Pathology

  • Biopsy results:
    • Malignant (biopsy-proven, n=271)
    • Benign (benign, n=140)
    • Benign (non-cancer callback screeners, n=115)
    • Benign (biopsy-proven benign, n=32)

Medical imaging

  • Digital Breast Tomography (DBT)
  • Breast ultrasound
  • Breast MR

Genomics

  • Potential linkage to genomics data through Segmed’s data ecosystem

Proteomics

  • Potential linkage to proteomics data through Segmed’s data ecosystem

Participant-reported data

  • Potential linkage to participant-reported data through Segmed’s data ecosystem

Biomarkers (Specific analyte measurements)

  • Potential linkage to biomarkers through Segmed’s data ecosystem